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Objective. To assess the validity of an exposure score obtained from the Xm2 tool for all pharmacological and nonpharmacological
strategies used by individuals to manage chronic pain. Methods. Using data from individuals with chronic pain, eXposure
multimodal (Xm2) scores were calculated by assigning one point for every 100mg of morphine equivalent used (opioid
medications); 25% of the maximum recommended exposure used (nonopioid medications); and any use of another strategy then
summed. Content, criterion, construct, and convergent validity were assessed. Results. 'e sample of 149 individuals used a mean
of 12.6 (SD � 4.6) strategies to manage pain and had a mean Xm2 score of 16.8 (SD � 9.1). Content validity was established by
demonstrating that the pain management strategies identiﬁed were also reported in the literature. Criterion validity was
established by the positive association of exposure scores with the following: interference with work (odds ratio (OR) � 2.23, 95%
conﬁdence interval (CI) � 1.14–4.36), daily activities (OR � 2.10, CI � 1.07–4.13), relationships (OR � 1.98, CI � 1.01–3.88), and
leisure activities (OR � 2.31, CI � 1.18–4.50); workdays missed (OR � 5.10, CI � 1.92–13.58); emergency department visits (OR �
3.40, CI � 1.17–9.91); hospitalizations (OR � 4.18, CI � 0.86–20.37); and by a negative association with satisfaction (OR � 0.40, CI
� 0.18–0.88). Construct validity was established by the positive association of exposure with baseline pain intensity (p< 0.01) and
odds of experiencing an adverse event (OR � 2.31, CI � 1.18–4.52). Convergent validity was established through correlations of
pain intensity from the Xm2 score and existing quantitative analgesic questionnaire (QAQ) score. Discussion. Xm2 scores
represent a valid estimate of total exposure to multimodal strategies used and provide clinically relevant information for deciding
what strategies to use at what level.
1. Introduction
Chronic pain is deﬁned by the American Chronic Pain As-
sociation as “ongoing or recurrent pain, lasting beyond the
usual course of acute illness or injury or more than three to six
months, andwhich adversely aﬀects the individual’s well being”
[1]. Chronic pain aﬀected approximately 25 million adults in
the United States (US) in 2012 [2]. Pain is a major cause of
disability and results in frequent physician visits, the need to
take medication, and poorer quality of life [3]. 'e total cost of
pain to society ranged from $560 to $635 billion (2010 US
dollars) per year in the US [3, 4]. Appropriate pain relief is
considered a basic human right, and individuals experiencing
pain should expect to receive adequate pain management [5].
However, adequatemanagement is dependent on the total dose
or exposure to all medications and other strategies used for
managing pain [3, 6]. 'at is, managing the concentration or
intensity, duration, and frequency of the exposure [7].
Population-based surveys of community dwelling
adults with chronic pain have shown that a wide variety of
strategies are used to manage pain. For example, strat-
egies include analgesic medications such as opioids
Hindawi
Pain Research and Management
Volume 2018, Article ID 2530286, 11 pages
https://doi.org/10.1155/2018/2530286
and nonsteroidal anti-inﬂammatory drugs (NSAIDs),
medications such as anticonvulsants and antidepressants,
and nonpharmacological strategies such as exercise, hot and
cold modalities, massage, and using dietary supplements
among many others [6, 8–24]. Despite the variety of
strategies used by individuals with pain, Breivik et al. [12]
found 40% to 64% of respondents indicated that their pain
management was unsatisfactory. However, these surveys do
not report doses of medications used or exposure level to
other management strategies. Given that the eﬀects of the
medications and other strategies are dependent on an ad-
equate exposure to the treatment strategy being used, it
would be helpful to be able to quantify actual exposure. If
actual exposure is not resulting in a therapeutic response,
then exposure can be adjusted up to the maximum rec-
ommended exposure (MRE) before adding or changing
treatment strategies. Despite the need for exposure in-
formation, a method for combining dose or exposure data
from pharmacological and nonpharmacological strategies is
not currently available.
A method for standardizing and combining pharma-
cological doses is available. 'e Quantitative Analgesic
Questionnaire (QAQ) was developed by Robinson-Papp
et al. [25] to assess adherence to pain medications by
standardizing doses based on percent of the maximum
recommended dose used or for opioids and standardizing
doses based on morphine milligram equivalents (MMEs)
calculated from the doses that patients say they actually use.
Actual dose used can then be compared to recommended
dose. 'e QAQ is limited though in that it does not include
medications that are not typically used for pain or any
nonpharmacological strategies.
In this study, we report an extension of the QAQ tool to
include nonpharmacological strategies, including medical
(e.g., physician visits), physical (e.g., exercise), psychological
(e.g., distraction), and self-initiated strategies (e.g., change
position) to obtain a total exposure score (eXposure multi-
modal, i.e., the Xm2 score) for all strategies used. Such a score
allows clinicians and researchers to relate the total exposure of
all strategies to outcomes, that is, to relate the use of both
pharmacological and nonpharmacological strategies to pain
intensity or to reduction of interference with daily activities. If
the Xm2 score is valid, then users can have conﬁdence that the
scores from the Xm2 tool represent total exposure to strategies
used by an individual to manage pain. 'e purpose of this
study was to (1) assess the validity of the Xm2 score estimated
for all strategies (pharmacological and nonpharmacological)
used by individuals to manage chronic pain and (2) discuss
the clinical relevance of the Xm2 scores.
2. Methods
2.1. Data Source. Data for testing the validity of the Xm2
score were obtained from a previous study [26] completed by
pharmacists who personally had chronic pain and who were
licensed in a southwestern state in the US. Pharmacists were
surveyed because they could provide detailed information
on their management strategies, including doses of medi-
cations [26].
'e survey collected data on the types and doses of
prescription and over-the-counter (OTC) medications used.
Data were also collected on medical strategies (e.g., surgery),
physical strategies (e.g., exercise), psychological strategies
(e.g., distraction), and self-initiated strategies (e.g., home
remedies) used; however, no data were obtained on the
exposure (dose) of the nonpharmacological strategies used.
Data also were collected on outcomes, including pain in-
tensity after treatment, interference with work, daily ac-
tivities, relationships, satisfaction with pain management
strategies, workdays lost, emergency department visits,
adverse events, and hospitalizations. Additionally, data on
pain (e.g., baseline pain levels) and demographic charac-
teristics were also collected. Further details are reported
elsewhere [26].
2.2. Exposure Scoring Procedure. A total exposure score was
calculated for each individual by adapting the methods
described by Robinson-Papp et al. [25], whereby points were
assigned according to the exposure (dose) of each medi-
cation used and summed. Points for opioid medications
were obtained by converting the dose to a weekly morphine
milligram equivalent (MME) and scored one point for every
100 milligrams (mg) of morphine equivalent used per week
(i.e., 1–99mg � one point, 100–199mg � two points, etc.).
For example, a score of 5 would indicate that an individual
was using between 400 MMEs and 499 MMEs of opioid per
week or 57–71 MMEs per day. Given that 57 MMEs per day
approximates the CDC’s recommended safe dose of 50
MMEs per day [27], we used 400 MMEs per week as a
benchmark for interpreting Xm2 scores for opioids. For
nonopioid prescription medications, one point was assigned
for every 25 percent of the maximum recommended ex-
posure (MRE) used (i.e., 1–24% � one point, 25–49% � two
points, etc.). For example, a score of 5 would indicate that a
speciﬁc nonopioid medication was being used at 100 to
124% of the maximum recommended exposure. Because
there were no data on exposure (dose) for nonmedication
strategies, we assigned one point for each nonmedication
strategy used, including medical, physical, psychological,
and self-initiated strategies.
2.3. Validity Assessment. 'e ﬁrst step in the validity as-
sessment was to describe the characteristics of the Xm2
scores. 'e score characteristics included the number and
range of the scores, as well as the categories of pain man-
agement identiﬁed. Interpretation of the scores is illustrated
so that validity can be considered in the context of the
information that the scores provide. 'e validity of the Xm2
tool was assessed by investigating the following: (1) content
validity; (2) criterion validity; (3) construct validity; and (4)
convergent validity.
2.3.1. Content Validity. Content validity has been deﬁned
as indicating if the sample of the target behaviors is rep-
resentative of the behaviors in the domain [28]. For
this study, content validity was assessed by examining the
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questionnaire, data, and source population. Evidence of
content validity was present if (1) the types of pain man-
agement strategies used for calculation of the Xm2 score
were representative of those used by individuals, (2) the
questionnaire to collect data on types (and doses) of self-
reported pain management strategies represented known
strategies (i.e., identiﬁed in the literature), and (3) the source
population had knowledge and experience with personal
pain management and were able to provide that information
via an online questionnaire.
2.3.2. Criterion Validity. Criterion validity can be deﬁned as
the association of a measure with outcomes [28]. Evidence of
criterion validity was present if exposure scores were as-
sociated with outcomes. We hypothesized that higher ex-
posure scores would be associated with more interference
with daily activities, leisure activities, work, relationships,
workdays lost, use of emergency departments, and hospital
admissions. In contrast, higher exposure scores would be
negatively related to satisfaction with pain management.
2.3.3. Construct Validity. Construct validity represents the
theory or the premise on which the score is based [28].
Evidence of construct validity was present if (1) higher
exposures were associated with higher levels of pain and (2)
exposure to greater numbers of strategies was associated
with a higher risk of adverse events. A multivariable re-
gression was conducted to explore whether the exposure
score was independently related to baseline pain and adverse
events.
2.3.4. Convergent Validity. Convergent validity compares
the measure under investigation to other measures of the
same construct [28]. Evidence of convergent validity was
present if the correlation of the Xm2 scores to baseline pain
were comparable to the correlation of the QAQ score with
baseline pain [25].
2.4. Data Analysis. A median split was used to categorize
exposure scores as low (below the median exposure score of
16) or high (equal to or greater than 16). Demographic
characteristics and outcomes were compared between the
low- and high-exposure groups using chi-square or Fisher’s
exact tests for nominal data and t-tests for normally dis-
tributed continuous data. To describe the distributions of the
exposure scores and the number of pain management
strategies used, a histogram was constructed to display Xm2
scores and number of strategies used versus the percent of
individuals with each score or number of strategies reported.
Findings related to construct and criterion validity were
reported as odds ratios with 95% conﬁdence intervals [29].
'e independence of the association between exposure
score and baseline pain was tested using multivariable linear
regression, and the independent association of exposure
score to adverse events was tested using multivariable lo-
gistic regression. In both models, the key independent
variable was exposure score, and characteristics of the
individuals were used as control variables. All covariates
were included in the linear model, while age, disability, and
employment status were included in the logistic model
(identiﬁed using the backward elimination technique). 'e
assumptions of the models were tested. An alpha value of
0.05 selected a priori was used to determine signiﬁcance.
Analyses were performed using SAS software version 9.4
(SAS Institute Inc., Cary, NC, USA).
3. Results
3.1.DemographicCharacteristics. Of the 149 respondents, 73
(49%) were in the low-exposure group and 76 (51%) in the
high-exposure group. Compared to the low-exposure group,
the high-exposure group reported signiﬁcantly higher
baseline pain levels (mean � 7.5 ± 1.9 vs. mean � 6.2 ± 2.1;
p< 0.01), more individuals with a disability (18.7% vs. 2.8%;
p< 0.01), and more individuals who had completed con-
tinuing education in pain management (93.2% vs. 81.9%;
p � 0.04). Individuals in the higher exposure group had
signiﬁcantly more emergency department visits in the last
ﬁve years due to pain (p � 0.02), more adverse events from
pain management strategies (p � 0.01), more pain in-
terference on daily activities (p � 0.03), more pain in-
terference on leisure activities (p � 0.01), more pain
interference on relationships (p< 0.05), more pain in-
terference on work (p � 0.02), and more workdays lost in
the last six months due to pain (p< 0.01) and were sig-
niﬁcantly less satisﬁed with their pain management strate-
gies than those in the lower exposure group (67.1% vs.
83.6%, respectively, p � 0.02) (Table 1).
3.2. Characteristics of the Xm2 Scores. As shown in Table 2,
Xm2 scores were available for 99 diﬀerent management
strategies that represented 15 categories of medications and
four nonpharmacological categories (medical strategies,
physical strategies, psychological strategies, and self-
initiated strategies). 'e Xm2 scores ranged from 1 to 15
for individual pharmacological strategies. Scores for non-
pharmacological strategies were 1 for all individual strategies
because there were no data on exposure level.
'e characteristics of the exposure levels, represented by
the Xm2 scores, also are shown in Table 2. 'e exposure
levels were generally moderate for both opioid and non-
opioid medications. 'e average Xm2 score for opioid use
was 3.2 (SD � 4.1; range � 1–15) representing about 80% of
the benchmark exposure of 400 MMEs per week or about 57
MMEs per day. However, the highest Xm2 score was 15,
which represents 3.75 times the benchmark of 400 MMEs
per week. 'e average Xm2 score for nonopioid medications
was 2.6 (SD � 3.1), 52% of theMRE (Xm2 score of 5).'e two
nonopioid medications with the highest Xm2 scores were
duloxetine (maximum Xm2 score � 9) and cyclobenzaprine
(maximum Xm2 score � 9); hence they were used at ex-
posures 1.8 times the recommended exposure.
'e range of the number of management strategies used
and the range of Xm2 scores are shown graphically in
Figure 1. 'e Xm2 scores for individual respondents (grey
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bars) ranged from 2 to 72 and had a distribution skewed to
the right. 'e mode was 10, the median 16, and the mean
16.8 (SD � 9.1); the coeﬃcient of variation was 54%. 'e
number of pain management strategies used by individuals
(black bars) ranged from 2 to 31 with a normal distribution.
'e mode was 12, the median 12, and the mean 12.6 (SD �
4.6); the coeﬃcient of variation was 37%.
3.3.EvidenceofContentValidity. 'equestionnaire required
respondents to report speciﬁc categories of prescription
therapies used and then identify the speciﬁc medication and
the total daily dose. A similar strategy was used for OTC
medications and nonpharmacological strategies, except re-
spondents did not provide dose data. An “other” category
allowed respondents to add strategies not speciﬁcally
identiﬁed in the questionnaire. Hence, the questionnaire was
able to collect data on all pain management strategies
recalled at the time of completion.
In general, the strategies included were identiﬁable in
the literature. A total of 99 diﬀerent strategies were
identiﬁed, including 13 diﬀerent classes of pharmaco-
logical strategies plus OTC products and “other.” Exam-
ples of nonpharmacological strategies included physical
activity, acupuncture, massage, meditation, relaxation,
avoiding speciﬁc activities, changing body position, diet
modiﬁcations, transcutaneous electrical nerve stimulation
(TENS), hot/cold packs, and rest (Table 2). Sixty-one
percent (60 of 99) of the strategies identiﬁed in this sur-
vey and 48% (31 of 65) of the prescription medications
represented classes of medications were present in the
literature [6, 8–24, 30–34].
Survey respondents were pharmacists who were highly
trained inmedicationmanagement describing their personal
pain management strategies and who had completed con-
tinuing education on pain management (87.7%). 'erefore,
there is evidence that the source population had the ability to
provide information on both types and exposure to pain
Table 1: Demographic characteristics and pain outcomes of study participants.
Characteristic Total (n � 149)
Xm2 score (points)
p value
Low (<16) (n � 73) High (≥16) (n � 76)
Baseline pain (n � 121) mean (standard deviation) 6.9 (2.1) 6.2 (2.1) 7.5 (1.9) <0.01
Age (n � 146) mean (standard deviation) 52.5 (13.9) 52.5 (13.8) 52.4 (14.1) 0.94
Sex, female (n � 147) N (%) 77 (52.4) 36 (50.0) 41 (54.7) 0.57
Race, white (n � 146) N (%) 131 (89.7) 64 (90.1) 67 (89.3) 0.87
Disability (n � 147) N (%) 16 (10.9) 2 (2.8) 14 (18.7) <0.01
Health status (n � 148) N (%)
Poor/fair 26 (17.6) 10 (13.9) 16 (21.1) 0.25
Good/excellent 122 (82.4) 62 (86.1) 60 (79.0)
Marital status, married (n � 143) N (%) 110 (76.9) 56 (81.2) 54 (73.0) 0.25
Employment status, employed (n � 148) N (%) 124 (83.8) 58 (80.6) 66 (86.8) 0.30
Primary professional practice site (n � 147) N (%)
Community 58 (39.5) 24 (33.3) 34 (45.3) 0.26
Hospital 25 (17.0) 12 (16.7) 13 (17.3)
Other 64 (43.5) 36 (50.0) 28 (37.3)
Completed continuing education on pain
management (n � 146) N (%) 128 (87.7) 59 (81.9) 69 (93.2) 0.04
Years practiced (n � 146) mean (standard deviation) 24.8 (14.5) 25.1 (15.0) 24.4 (14.1) 0.77
Hospital admissions in last ﬁve years due to pain (n �
149) N (%) 10 (6.7) 2 (2.7) 8 (10.5) 0.10
Emergency department visits in last ﬁve years due to
pain (n � 148) N (%) 20 (13.5) 5 (6.9) 15 (20.0) 0.02
Adverse events from any strategies used (n � 147) N
(%) 62 (42.2) 23 (31.9) 39 (52.0) 0.01
Pain interference on daily activities (n � 148) N (%) 92 (62.2) 39 (53.4) 53 (70.7) 0.03
Pain interference on leisure activities (n � 148) N (%) 86 (58.1) 35 (48.0) 51 (68.0) 0.01
Pain interference on relationships (n � 149) N (%) 57 (38.3) 22 (30.1) 35 (46.1) <0.05
Pain interference on work (n � 148) N (%) 61 (41.2) 23 (31.5) 38 (50.7) 0.02
Satisfaction with pain management strategies (n �
149) N (%) 112 (75.2) 61 (83.6) 51 (67.1) 0.02
Workdays lost in last six months due to pain (n � 138)
N (%) 28 (20.3) 6 (8.6) 22 (32.4) <0.01
Pain intensity after treatment (n � 136) mean
(standard deviation) 3.2 (2.2) 3.0 (2.3) 3.3 (2.1) 0.54
Percent pain relief from all strategies (n � 149) mean
(standard deviation) 69.1 (20.4) 70.8 (20.8) 67.4 (20.1) 0.32
All comparisons conducted between low- and high-exposure groups using t-test for baseline pain, age, and years practiced and chi-squared test for all
remaining variables.
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Table 2: Number of individuals using each pain management strategy identiﬁed in the study organized by low or high Xm2 score and
maximum Xm2 score for each strategy.
Pain management strategy
Individuals using each strategy N (%)
Maximum
Xm2 scoreTotal (n � 149) Low Xm
2 score (<16 points)
(n � 73)
High Xm2 score (≥16 points)
(n � 76)
Prescription medications
Use of an opioid∗ 49 (32.9) 11 38 15
Codeine∗ 3 (2.0) 1 2 2
Fentanyl∗ 1 (0.7) 0 1 1
Hydrocodone∗ 26 (17.4) 5 21 6
Hydromorphone 1 (0.7) 0 1 7
Methadone 1 (0.7) 0 1 13
Morphine∗ 2 (1.3) 0 2 13
Oxycodone∗ 13 (8.7) 2 11 15
Tramadol∗ 11 (7.4) 3 8 3
Use of a nonopioid 125 (83.9) 51 74 9
Analgesics∗
Acetaminophen∗ 36 (24.2) 6 30 3
Dichloralphenazone 1 (0.7) 0 1 2
Anticonvulsants∗
Carbamazepine∗ 1 (0.7) 1 0 3
Gabapentin∗ 17 (11.4) 5 12 4
Lamotrigine∗ 1 (0.7) 0 1 2
Levetiracetam∗ 1 (0.7) 0 1 3
Pregabalin 2 (1.3) 2 0 2
Topiramate 3 (2.0) 0 3 2
Valproic acid 1 (0.7) 0 1 3
Antidepressants∗
Amitriptyline∗ 8 (5.4) 2 6 7
Bupropion 1 (0.7) 0 1 2
Duloxetine∗ 12 (8.1) 1 11 9
Fluoxetine∗ 1 (0.7) 0 1 3
Mirtazapine 1 (0.7) 0 1 2
Nortriptyline 4 (2.7) 0 4 4
Sertraline 2 (1.3) 0 2 3
Trazodone 2 (1.3) 0 2 2
Venlafaxine∗ 4 (2.7) 0 4 6
Vilazodone 1 (0.7) 0 1 5
Antipsychotic
Quetiapine 1 (0.7) 0 1 1
Barbiturate∗
Butalbital∗ 3 (2.0) 0 3 5
Beta blockers∗
Atenolol 1 (0.7) 0 1 3
Metoprolol 3 (2.0) 0 3 2
Propanolol 3 (2.0) 0 3 4
Calcium channel blockers∗
Amlodipine 1 (0.7) 0 1 5
Verapamil 1 (0.7) 0 1 3
Muscle relaxants∗
Baclofen 1 (0.7) 0 1 2
Carisoprodol 9 (6.0) 1 8 5
Chlorzoxazone 1 (0.7) 0 1 2
Cyclobenzaprine∗ 29 (19.5) 5 24 9
Metaxalone 4 (2.7) 0 4 4
Methocarbamol∗ 6 (4.0) 1 5 2
Orphenadrine 1 (0.7) 0 1 3
Tizanidine 3 (2.0) 0 3 1
Nonsteroidal anti-inﬂammatory drugs∗
Celecoxib∗ 9 (6.0) 0 9 5
Diclofenac∗ 7 (4.7) 1 6 5
Etodolac∗ 2 (1.3) 1 1 5
Pain Research and Management 5
Table 2: Continued.
Pain management strategy
Individuals using each strategy N (%)
Maximum
Xm2 scoreTotal (n � 149) Low Xm
2 score (<16 points)
(n � 73)
High Xm2 score (≥16 points)
(n � 76)
Ibuprofen∗ 58 (38.9) 27 31 4
Indomethacin∗ 2 (1.3) 0 2 2
Meloxicam∗ 12 (8.1) 1 11 5
Nabumetone 4 (2.7) 1 3 4
Naproxen∗ 37 (24.8) 13 24 4
Salsalate 2 (1.3) 0 2 2
Sulindac 1 (0.7) 1 0 3
Tolmetin 1 (0.7) 0 1 3
Sedatives
Alprazolam∗ 1 (0.7) 0 1 1
Diazepam∗ 1 (0.7) 0 1 3
Lorazepam∗ 2 (1.3) 0 2 1
Steroids∗
Methylprednisolone∗ 1 (0.7) 0 1 1
Prednisolone∗ 1 (0.7) 0 1 1
Triptans∗
Eletriptan 3 (2.0) 0 3 3
Naratriptan 1 (0.7) 0 1 3
Rizatriptan 4 (2.7) 1 3 2
Sumatriptan∗ 5 (3.4) 0 5 3
Zolmitriptan 2 (1.3) 1 1 3
Others
Caﬀeine 3 (2.0) 0 3 1
Isometheptene 1 (0.7) 0 1 2
Nonprescription medications∗
Acetaminophen∗ 64 (43.0) 28 36 1
Aspirin∗ 16 (10.7) 8 8 1
Benadryl 1 (0.7) 0 1 1
Excedrin∗ 2 (1.3) 1 1 1
Famotidine 1 (0.7) 0 1 1
Herbals∗ 16 (10.7) 7 9 1
NSAIDs∗ 95 (63.8) 48 47 1
Supplement∗ 11 (7.4) 3 8 1
Medical strategies
Chiropractor∗ 32 (21.5) 12 20 1
Nasal spray 1 (0.7) 0 1 1
Other injections∗ 1 (0.7) 0 1 1
Patch∗ 2 (1.3) 0 2 1
Surgery∗ 31 (20.8) 5 26 1
Steroid injections 50 (33.6) 10 40 1
Topical products∗ 15 (10.1) 5 10 1
Physical strategies
Acupuncture∗ 21 (14.1) 6 15 1
Massage∗ 92 (61.7) 39 53 1
Physical activity∗ 105 (70.5) 44 61 1
Physical therapy∗ 81 (54.4) 27 54 1
Stretching∗ 5 (3.4) 5 0 1
TENS∗ 51 (34.2) 14 37 1
Psychological strategies
Meditation∗ 42 (28.2) 12 30 1
Relaxation∗ 89 (59.7) 31 58 1
Self-initiated strategies
Alcohol∗ 1 (0.7) 1 0 1
Avoid speciﬁc activities∗ 104 (69.8) 43 61 1
Cannabis/Heroin∗ 3 (2.0) 0 3 1
Changing body position∗ 132 (88.6) 61 71 1
Diet∗ 3 (2.0) 2 1 1
Education 38 (25.5) 12 26 1
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management strategies. Overall, the evidence is more than
adequate for content validity.
3.4. Evidence of Criterion Validity. 'ere is also substantial
evidence that the exposure score is related to pain outcomes
as is required for criterion validity. As shown in Table 1 and
Figures 2 and 3, the association of the exposure score was
positive for all outcomes except satisfaction, which had a
negative association as expected.
3.5. Evidence of Construct Validity. Assessment of the
purported association between the Xm2 scores and baseline
pain and adverse events both provided evidence for con-
struct validity. Baseline pain was positively related to ex-
posure; the higher the level of baseline pain, the higher the
exposure score (p< 0.01; see Table 1). 'at is, the higher the
level of baseline pain, the more management strategies with
higher exposures were used to manage the pain. A similar
positive association was found for adverse events; the higher
the exposure score, the greater the proportion of re-
spondents who had experienced an adverse event (OR �
2.31, 95% CI � 1.18–4.52; see Figure 3).
'e multivariable linear regression model (adjusted for
age, sex, race, disability status, health status, marital status,
employment status, years practiced, professional practice
site, and completed continuing education on pain) for ex-
posure score on baseline pain indicated that for every one
unit increase in exposure score, mean baseline pain in-
creased by 0.07 (standard error 0.03, p � 0.01, r2 � 0.22).
'e regression also indicated that exposure is an in-
dependent predictor of baseline pain and hence is not an
artifact of an associated variable. 'e multivariable logistic
regression model (adjusted for age, employment status, and
disability) for exposure score on adverse events indicated
that for every one unit increase in exposure score, the odds of
having experienced an adverse event increased by eight
percent (OR � 1.08, 95% CI � 1.07–1.15, p � 0.01, c-statistic
� 0.79). Exposure was also an independent predictor of
adverse events.
3.6. Evidence of ConvergentValidity. Evidence of convergent
validity was available from a comparison of the correlation
between Xm2 and the QAQ scores and patient-reported
baseline pain intensity. Our adjusted multivariable linear
regression (described above) indicated an increase in
baseline pain as exposure score increased, and Robinson-
Papp et al. report that their QAQ score was correlated with
patient-reported pain intensity (r � 0.38, p< 0.001).
4. Discussion
To the best of our knowledge, this is the ﬁrst study to show
that an overall score indicating level of exposure to all pain
management strategies, pharmacological and non-
pharmacological, can provide valid information and has a
clinically meaningful association with baseline pain and
outcomes such as interference, emergency department use,
and hospitalizations. Because the Xm2 score is based on
quartiles of the recommended total exposure, it represents
ratio level measurement with a meaningful zero and equal
intervals for nonopioid management strategies. Hence, the
score is standardized and is comparable regardless of the
speciﬁc strategy being considered or the level of the rec-
ommended maximum exposure.
A score that is valid can provide a variety of clinically
relevant information. First, the Xm2 score is informative
because it describes what individuals are actually doing to
manage their pain, and individuals in this sample were clearly
using multimodal strategies. 'e average individual used 12.6
diﬀerent strategies and had an average Xm2 score of 16.8. It
appears that by using more strategies at a higher exposure
level, individuals with higher levels of pain were able to
achieve posttreatment levels of pain similar to the lower pain
group. Second, the Xm2 score indicates the level at which each
strategy is being used; hence, it is possible to identify whether
speciﬁc strategies are being overused or underused.
'e Xm2 score also enables the clinician to obtain an
estimate of risk for adverse events and interference in ac-
tivities. Individuals with Xm2 scores at or above the median
(16) were more than two times more likely to experience an
adverse event or interference with work, daily activities,
leisure activities, and relationships than the lower exposure
group even though there were no diﬀerences in posttreat-
ment pain intensity.
Our ﬁndings also showed that pharmacists in this study
were knowledgeable about diﬀerent pain management
strategies. Given that pharmacists are highly trained and
accessible healthcare professionals, health systems should
consider expanded roles for pharmacists in helping in-
dividuals in the general population manage their chronic
pain. Use of the Xm2 score, in collaboration with healthcare
Table 2: Continued.
Pain management strategy
Individuals using each strategy N (%)
Maximum
Xm2 scoreTotal (n � 149) Low Xm
2 score (<16 points)
(n � 73)
High Xm2 score (≥16 points)
(n � 76)
Essential oils∗ 1 (0.7) 0 1 1
Hot bath or shower∗ 96 (64.4) 39 57 1
Hot or cold packs∗ 99 (66.4) 36 63 1
Rest∗ 125 (83.9) 56 69 1
Unspeciﬁed∗ 59 (39.6) 27 32 1
TENS � transcutaneous electrical nerve stimulation. 'e minimum score is 0 in all cases. ∗Indicates the strategy was also identiﬁed in the literature. An Xm2
score of 5 indicates that item is being used at 100 to 124% of the recommended maximum exposure (RME).
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professionals such as pharmacists or physicians, may help
individuals manage their pain more eectively and conse-
quently improve their quality of life.
Robinson-Papp et al. [25] initially developed the
scoring system used here to assess adherence that also
provides useful information to clinicians. We have
shown that the scoring system can be expanded to
include nonpharmacological strategies for managing
pain and that the scores provide information beyond
adherence to enable clinicians to improve decision
Quantity of pain management strategies
Exposure score
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Figure 1: Percent of individuals using each number of pain self-management strategies and percent of individuals assigned each exposure
score. e black bars indicate the number of pain management strategies used. e grey bars indicate the exposure score. For example,
Figure 1 shows 10.1% of individuals used 10 pain management strategies and 8.7% of individuals had an exposure score of 10, while 0.7% of
individuals used 20 pain management strategies and 2% of individuals had an exposure score of 20. Mean number of strategies used  12.6
(standard deviation  4.6). Mean exposure score  16.8 (standard deviation  9.1).
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Figure 2: Percent of individuals reporting interference in the low- or high-exposure score groups. Daily  interference on daily activities:
OR  2.10 (95% CI  1.07–4.13). Leisure  interference on leisure activities: OR  2.31 (95% CI  1.18–4.50). Work  interference on work:
OR  2.23 (95%CI  1.14–4.36). Relationships  interference on relationships: OR  1.98 (95%CI  1.01–3.88). For example, Figure 2 shows
that 53% of individuals in the low-exposure group and 71% of individuals in the high-exposure group reported that pain interfered with their
daily activities.
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making related to the quantity and exposure to each
strategy used for managing pain.
Although the Xm2 scores were shown to be valid and
provide useful information, they are limited in that there
were no data available on exposure level for non-
pharmacological strategies. Each nonpharmacological
strategy was scored 1 that represents up to 24% of the
MRE. Hence, nonpharmacological strategies contributed
limited information to the Xm2 score. Part of the issue
for nonpharmacological strategies is dening the MRE.
ere is currently an attempt to establish a recom-
mended exposure for chiropractic care, specically an
approach known as spinal manipulation [35]. Perhaps
that eort will provide a model for establishing recom-
mended exposure for other nonpharmacological strate-
gies in future.
Additionally, more work is needed to assure the scoring
for opioids is consistent with nonopioids. Robinson-Papp
et al. [25] did not relate opioid exposure to a MRE so we
adapted the approach by using 400 MMEs (57 MMEs) to
represent a benchmark for interpretation of scores for
opioids. ere does not appear to be consensus on the MRE
for opioids although the CDC has produced some guidance
[27], however, further eorts perhaps involving a Delphi
panel are needed.
4.1. Implications for Future Research. Based on the ndings
from this study, we recommend that future research into
pain management from a patient perspective includes a
measure of treatment burden. Individuals in this study were
using up to 31 dierent strategies (average 12.6) to manage
their pain, which represents a substantial treatment burden.
Indeed the large number of strategies used by the higher
exposure group may be reected in the higher ratings for
pain interference and with the reduced satisfaction with
their pain management.
More studies are needed on self-reported pain man-
agement strategies. Studies using clinical data (e.g., chart
reviews) are limited in that nonpharmacological strategies
are not likely to be identied. Also, this study did not provide
information on pain management strategies used by the
general population; this was a group with expertise in pain
management that may have resulted in their using more
strategies than the average person. Given that they appeared
to be able to reduce their pain on average to tolerable levels
using a large number of strategies to manage their pain,
further investigation into the use of multiple strategies seems
worthwhile.
A third area for additional research is related to the
development of an Xm2 tool that could be used by the
general population. A website or an “app” that assists pa-
tients with reviewing their pain management strategies
should be useful. For example, an individual could identify
that they are not using nonpharmacological strategies such
as exercise, psychological strategies, or even simple self-
initiated strategies such as changing position and could
add them to their pain management plan. Further, it may
increase individuals’ ability to understand that they need to
use management strategies at a specic level to benet from
them that may increase adherence.
4.2. Limitations. ere were several limitations to this study.
e sample size was relatively small and not representative of
the general population.e sample also consisted of licensed
pharmacists; individuals with more extreme pain may no
longer be working or licensed, thus truncating our ndings.
However, for testing a new tool, it was benecial to have a
sample with expertise as individuals needed to provide the
exposure information via an online questionnaire that would
be di¥cult for the general population. Use of a questionnaire
also introduces the likelihood of response bias and is limited
by subjects’ inability to recall accurately.
4.3. Conclusion. Initial testing of the Xm2 tool indicates
that Xm2 scores represent a valid estimate of total exposure
to multimodal strategies and that they can provide clin-
ically relevant information to inform decisions concerning
which strategies to use at what level for managing chronic
pain.
Data Availability
e survey data used to support the ndings of this study are
available from the corresponding author upon request.
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Figure 3: Percent of individuals reporting pain outcomes in the
low- or high-exposure score groups. Satisfaction  satisfaction with
pain management strategies: OR  0.40 (95% CI  0.18–0.88).
Adverse  adverse events from pain management strategies: OR 
2.31 (95%CI  1.18–4.52).Workdays workdays lost due to pain in
past six months: OR  5.10 (1.92–13.58). Emergency  emergency
department visits due to pain in past ve years: OR  3.40 (95% CI
 1.17–9.91). Hospital  hospital admissions due to pain in past ve
years: OR  4.18 (95% CI  0.86–20.37). For example, Figure 3
shows that 32% of individuals in the low-exposure group and 52%
of individuals in the high-exposure group reported that they had
experienced an adverse event due to their pain management
strategies.
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